InvestSMART

Recce Pharmaceuticals Ltd (ASX: RCE) - Announcements

Current share price for RCE : $0.280 0.01 (3.45%)+

ASX company news and announcements for Recce Pharmaceuticals Ltd (RCE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Recce Pharmaceuticals Ltd (RCE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Recce Pharmaceuticals Ltd (RCE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Recce Pharmaceuticals Ltd (RCE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$86 Proposed issue of securities - RCE 11 Sep 2023 9:52AM $0.650 $0.280 fallen by 56.92%
$86 Placement and Entitlement Offer 11 Sep 2023 9:52AM $0.650 $0.280 fallen by 56.92%
$86 Trading Halt 8 Sep 2023 9:41AM $0.650 $0.280 fallen by 56.92%
$86 Opening R&D Address at World AMR Congress 8 Sep 2023 9:07AM $0.650 $0.280 fallen by 56.92%
$86 RECCE Trademark Registered - Vietnam 6 Sep 2023 9:41AM $0.690 $0.280 fallen by 59.42%
$86 Additional Positive Patient Cases - Special Access Scheme 31 Aug 2023 3:40PM $0.700 $0.280 fallen by 60%
$86 Appendix 4E and Unaudited Preliminary Report 31 Aug 2023 3:34PM $0.700 $0.280 fallen by 60%
$86 Next Dose Cleared in Rapid Infusion Phase I/II UTI Trial 28 Aug 2023 1:50PM $0.685 $0.280 fallen by 59.12%
$86 Patients Dosed in R327 Diabetic Foot Infection Trial 22 Aug 2023 10:44AM $0.700 $0.280 fallen by 60%
$86 Phase I/II Burn Wound Infection Trial Stage 1 Complete 21 Aug 2023 12:42PM $0.730 $0.280 fallen by 61.64%
$86 Positive Patients Update - Special Access Scheme 8 Aug 2023 8:23AM $0.610 $0.280 fallen by 54.10%
$86 Australian Patent Granted for RECCE Anti-Infectives 3 Aug 2023 3:11PM $0.590 $0.280 fallen by 52.54%
$86 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jul 2023 6:15PM $0.715 $0.280 fallen by 60.84%
$86 Bonus Canadian R&D Rebate Received 28 Jul 2023 12:44PM $0.710 $0.280 fallen by 60.56%
$86 Scientia Completes Cohort Dosing in Phase I/II UTI Trial 28 Jul 2023 10:20AM $0.705 $0.280 fallen by 60.28%
$86 Abstract & Poster Presentation at US Military Symposium 27 Jul 2023 9:46AM $0.705 $0.280 fallen by 60.28%
$86 Scientia Doses Ahead of Schedule in Phase I/II UTI Trial 24 Jul 2023 1:42PM $0.700 $0.280 fallen by 60%
$86 Clarification - 5x Higher Concentration in Urine & Plasma 20 Jul 2023 10:16AM $0.735 $0.280 fallen by 61.90%
$86 Phase I Clinical Trial Data Review Complete 19 Jul 2023 10:08AM $0.670 $0.280 fallen by 58.21%
$86 A$801,604 R&D Rebate Advance Received 12 Jul 2023 11:13AM $0.630 $0.280 fallen by 55.56%
$86 First Cohort Dosed in Rapid Infusion Phase I/II UTI study 10 Jul 2023 10:31AM $0.630 $0.280 fallen by 55.56%
$86 Ethics Approval for Phase I/II UTI Trial Expansion 29 Jun 2023 1:49PM $0.610 $0.280 fallen by 54.10%
$86 Change of Director's Interest Notice - J Graham 26 Jun 2023 3:58PM $0.565 $0.280 fallen by 50.44%
$86 DFI Clinical Trial Outpatient Nurses Appointed 29 May 2023 10:54AM $0.585 $0.280 fallen by 52.14%
$86 WA Government Sponsorship for BIO Korea 2023 8 May 2023 9:36AM $0.660 $0.280 fallen by 57.58%

226 - 250 of 733 results

Page 10 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.